Operating CF
118.59B DKK
Capex
−87.57B DKK
Free Cash Flow
31.03B DKK
FCF Margin
+26.2%
Cash flow waterfall for Novo Nordisk (NVO) — TTM through Q1 2026
Free cash flow: 31.03B DKK
Cash flow breakdown for Novo Nordisk (NVO) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | 118.59B DKK | 118.59B DKK |
| Capital Expenditure | −87.57B DKK | 31.03B DKK |
| Free Cash Flow | 31.03B DKK | 31.03B DKK |
| Other Investing | 3.37B DKK | 34.40B DKK |
| Share Buybacks | −2.40B DKK | 32.00B DKK |
| Dividends Paid | −51.80B DKK | −19.80B DKK |
| Net Debt Change | 24.16B DKK | 4.35B DKK |
| Other Financing & FX | −22.16B DKK | −17.81B DKK |
| Net Cash Decrease | −17.81B DKK | −17.81B DKK |
- Operating Cash Flow118.59B DKK
- Capital Expenditure−87.57B DKK
- Free Cash Flow31.03B DKK
- Other Investing3.37B DKK
- Share Buybacks−2.40B DKK
- Dividends Paid−51.80B DKK
- Net Debt Change24.16B DKK
- Other Financing & FX−22.16B DKK
- Net Cash Decrease−17.81B DKK
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement